Upgrade to SI Premium - Free Trial

vTv Therapeutics (VTVT)

21.28 +3.11 (17.12%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (7/31/24 *Est.)

Latest Headlines

CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING May 28, 2024 8:00 AM - PR NewsWire CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF PANCREATIC CANCER May 20, 2024 12:00 PM - PR NewsWire vTv Therapeutics (VTVT) Misses Q1 EPS by 117c May 9, 2024 6:21 PM - StreetInsider vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update May 9, 2024 4:51 PM - Globe NewsWire Form 10-Q vTv Therapeutics Inc. For: Mar 31 May 9, 2024 4:33 PM - SEC Filing Form 8-K vTv Therapeutics Inc. For: May 09 May 9, 2024 4:28 PM - SEC Filing Form EFFECT vTv Therapeutics Inc. April 30, 2024 6:09 AM - SEC Filing Form 424B2 vTv Therapeutics Inc. April 29, 2024 4:30 PM - SEC Filing Form 424B2 vTv Therapeutics Inc. April 29, 2024 4:27 PM - SEC Filing Form DEF 14A vTv Therapeutics Inc. For: Jun 11 April 26, 2024 10:44 AM - SEC Filing Form S-3 vTv Therapeutics Inc. April 10, 2024 5:11 PM - SEC Filing vTv Therapeutics (VTVT) Regains Nasdaq Compliance March 26, 2024 4:37 PM - StreetInsider Form 8-K vTv Therapeutics Inc. For: Mar 25 March 26, 2024 4:36 PM - SEC Filing Form SC 13D/A vTv Therapeutics Inc. Filed by: MacAndrews & Forbes Inc. March 22, 2024 4:57 PM - SEC Filing CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT March 19, 2024 8:30 AM - PR NewsWire Form 3 vTv Therapeutics Inc. For: Mar 13 Filed by: Phillips Anne M. March 14, 2024 8:01 AM - SEC Filing Form 8-K vTv Therapeutics Inc. For: Mar 13 March 14, 2024 7:58 AM - SEC Filing Full Article List